Abstract
A mechanism-based pharmacokinetic-pharmacodynamic (PK/PD) model for neuroactive steroids, comprising a separate characterization of 1) the receptor activation process and 2) the stimulus-response relationship, was applied to various nonsteroidal GABAA receptor modulators. The EEG effects of nine prototypical GABAAreceptor modulators (six benzodiazepines, one imidazopyridine, one cyclopyrrolone, and one β-carboline) were determined in rats in conjunction with plasma concentrations. Population PK/PD modeling revealed monophasic concentration-EEG effect relationships with large differences in potency (EC50) and intrinsic activity between the compounds. The data were analyzed on the basis of the mechanism-based PK/PD model for (synthetic) neuroactive steroids on the assumption of a single and unique stimulus-response relationship. The model converged yielding estimates of both the apparent in vivo receptor affinity (KPD) and the in vivo intrinsic efficacy (ePD). The values ofKPD ranged from 0.41 ± 0 ng·ml−1 for bretazenil to 436 ± 72 ng·ml−1 for clobazam and the values forePD from −0.27 ± 0 for methyl 6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate to 0.54 ± 0.02 for diazepam. Significant linear correlations were observed between KPD for unbound concentrations and the affinity in an in vitro receptor bioassay (r = 0.93) and between ePD and the GABA-shift in vitro (r = 0.95). The findings of this investigation show that the in vivo effects of nonsteroidal GABAA receptor modulators and (synthetic) neuroactive steroids can be described on the basis of a single unique transducer function. In this paradigm, the nonsteroidal GABAA receptor modulators behave as partial agonists relative to neuroactive steroids.
Footnotes
-
↵1 Current address: AstraZeneca R&D Södertälje, DMPK and BAC, S 15185 Södertälje, Sweden.
-
DOI: 10.1124/jpet.102.042341
- Abbreviations:
- PK/PD
- pharmacokinetic/pharmacodynamic
- DMCM
- methyl 6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate
- HPLC
- high-pressure liquid chromatography
- CCV
- constant coefficient of variation
- FOCE
- first-order estimation method with interaction
- ORG 21465
- 2β-3α-5α-3-hydroxy-2-(2,2-dimethylmorpholin-4-yl)-pregnan-11,20-dione
- ORG 20599
- 2β-3α-5α-21-chloro-3-hydroxy-2-(4-morpholinyl)-pregnan-20-one
- Received July 30, 2002.
- Accepted September 18, 2002.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|